8-K
filed December 17, 2025, 6:59 PM ET
ticker HBIO
CIK 0001123494
debt
confidence high
sentiment positive
materiality 0.80
HARVARD BIOSCIENCE INC (HBIO): debt financing — Harvard Bioscience closes $40M debt refinancing with BroadOak; extends maturity to 2029, appoints new director
HARVARD BIOSCIENCE INC
- Enters $40M senior secured credit facility (Term A $10M, Term B $22.5M, Term C $7.5M convertible at $1.00) maturing Dec 17, 2029
- Issues warrants to purchase 2M shares of common stock at $0.50 per share; proceeds repay existing Citizens Bank credit facility
- Quarterly amortization on Term A/B begins Dec 31, 2027; amortization and maturity can extend 1 year upon EBITDA milestone
- Appoints Bill Snider (BroadOak Partner) to Board and Compensation Committee; will form Product, Operations & Scientific Advisory Board
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
HARVARD BIOSCIENCE INC incurred term loan of $10.0 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
- Instrument
- term loan
- Principal
- $10.0 million
- Counterparty
- BroadOak Income Fund, L.P.
- Rate
- greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
- Maturity
- December 17, 2029
- Event
- incurrence
Exact text from the filing
The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
HARVARD BIOSCIENCE INC incurred convertible notes of $7.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
- Instrument
- convertible notes
- Principal
- $7.5 million
- Counterparty
- BroadOak Income Fund, L.P.
- Rate
- greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
- Maturity
- December 17, 2029
- Event
- incurrence
Exact text from the filing
The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
HARVARD BIOSCIENCE INC incurred term loan of $22.5 million with BroadOak Income Fund, L.P. at greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree maturing December 17, 2029.
- Instrument
- term loan
- Principal
- $22.5 million
- Counterparty
- BroadOak Income Fund, L.P.
- Rate
- greater of (i) 12.80% from the date of the Loan Agreement through the Loan Agree
- Maturity
- December 17, 2029
- Event
- incurrence
Exact text from the filing
The Loan Agreement provides for the following term loans: (i) a term loan in an aggregate principal amount of $10.0 million (the “Term A Loan”), (ii) a term loan in an aggregate principal amount of $22.5 million (the “Term B Loan”) and (iii) a term loan in an aggregate principal amount of $7.5 million (the “Term C Loan”
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HARVARD BIOSCIENCE INC entered into Loan and Security Agreement with certain financial institutions party thereto as lenders and BroadOak Income Fund, L.P., as administrative agent valued at $10.0 million, $22.5 million and $7.5 million (effective 2025-12-17).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- certain financial institutions party thereto as lenders and BroadOak Income Fund, L.P., as administrative agent
- Value
- $10.0 million, $22.5 million and $7.5 million
- Effective
- 2025-12-17
Exact text from the filing
On December 17, 2025, Harvard Bioscience, Inc. (the “Company”), as borrower, entered into a Loan and Security Agreement (the “Loan Agreement”) with certain financial institutions party thereto as lenders (the “Lenders”) and BroadOak Income Fund, L.P. (“BroadOak”), as the administrative agent and collateral agent
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.